Clobazam (Onfi) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Clobazam (Onfi)
Marketed by Lundbeck LLC and partners
NCT00518713 · Phase 3 · completed
The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.
Reported efficacy
Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) (met)
Result source: NCT00518713
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
Reported efficacy
Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)
Result source: NCT01390220
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clobazam (Onfi) | Midazolam (Nayzilam) |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not reported |
| 50% responder rate | —Not reported | —Not reported |
| Seizure freedom | —Not reported | 54.8% vs 38.7%+16.1 vs placeboNCT01999777 |
Seizure frequency, % change
- Clobazam (Onfi)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
50% responder rate
- Clobazam (Onfi)
- —Not reported
- Midazolam (Nayzilam)
- —Not reported
Seizure freedom
- Clobazam (Onfi)
- —Not reported
- Midazolam (Nayzilam)
- 54.8% vs 38.7%+16.1 vs placeboNCT01999777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clobazam (Onfi): 4 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clobazam (Onfi) | Midazolam (Nayzilam) |
|---|---|---|
| Dropout rate | 30.5%high dosea NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 show 4 more results13.8%low dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 27.4%medium dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 29.6% NCT01160770 · Phase 3 · monotherapy 10% NCT03371836 · Phase 4 · registry result, not featured evidence | —5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 31.2%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Discontinued due to AEs | —high dosea NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 show 4 more results—low dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 —medium dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 3.7% NCT01160770 · Phase 3 · monotherapy — NCT03371836 · Phase 4 · registry result, not featured evidence | —5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 5.8%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 — NCT01999777 · Phase 3 · monotherapy |
| Serious AEs | 8.5%high dosea NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 show 4 more results5.2%low dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 9.7%medium dose NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 43.1% NCT01160770 · Phase 3 · monotherapy — NCT03371836 · Phase 4 · registry result, not featured evidence | 0%5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results0%5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 0.7%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Most frequent reported AEs | high dosea somnolence 25.4% (placebo 11.9%) lethargy 15.3% (placebo 5.1%) aggression 13.6% (placebo 5.1%) NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 show 3 more resultslow dose pyrexia 17.2% (placebo 3.4%) somnolence 15.5% (placebo 11.9%) lethargy 10.3% (placebo 5.1%) NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 medium dose somnolence 24.2% (placebo 11.9%) drooling 12.9% (placebo 3.4%) upper respiratory tract infection 12.9% (placebo 10.2%) NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 upper respiratory tract infection 28.1% pyrexia 18% somnolence 16.9% NCT01160770 · Phase 3 · monotherapy | 5 mg + 5 mgb nasal discomfort 16.3% (placebo 7.3%) somnolence 9.3% (placebo 9.8%) throat irritation 7% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 show 3 more results5 mg only somnolence 9.9% (placebo 9.8%) headache 6.6% (placebo 0%) nasal discomfort 5.5% (placebo 7.3%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 7.3%) somnolence 9.6% (placebo 9.8%) lacrimation increased 6.8% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 16.1%) nausea 9.7% (placebo 3.2%) throat irritation 9.7% (placebo 9.7%) NCT01999777 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clobazam (Onfi)
show 11 more results
Midazolam (Nayzilam)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Onfi)'s landscape · Midazolam (Nayzilam)'s landscape